Trulieve Cannabis Corp. splits its revenue into 5 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Retail at $1.1 billion, 94% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
|---|---|---|---|---|---|---|
| Revenue |
1,081
|
1,181
|
1,186
|
1,129
|
1,218
|
932
|
| Retail |
—
|
1,110
-1.6%
share 94.0%
|
1,129
+4.2%
share 95.1%
|
1,084
-6.5%
share 96.0%
|
1,158
+33.2%
share 95.1%
|
870
share 93.3%
|
| Wholesale And Other |
—
|
71
+22.8%
share 6.0%
|
58
share 4.9%
|
—
|
—
|
—
|
| Wholesale Licensing And Other |
—
|
—
|
—
|
—
|
—
|
68
share 7.3%
|
| Wholesale |
—
|
—
|
—
|
43
-21.2%
share 3.8%
|
55
-9.9%
share 4.5%
|
61
share 6.6%
|
| License |
—
|
—
|
—
|
2
-51.6%
share 0.2%
|
5
+328.2%
share 0.4%
|
1
share 0.1%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- TRLV (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Tallahassee, FL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1754195
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Source: SEC EDGAR filings. This is company-reported data, not investment advice.